<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(4)</volume><submitter>Signore A</submitter><pubmed_abstract>Molecular medicine has gained clinical relevance for the detection and staging of oncological diseases, to guide therapy decision making and for therapy follow-up due to the availability of new highly sensitive hybrid imaging camera systems and the development of new tailored radiopharmaceuticals that target specific molecules. The knowledge of the expression of different receptors on the primary tumor and on metastases is important for both therapeutic and prognostic purposes and several approaches are available aiming to achieve personalized medicine in different oncological diseases. In this review, we describe the use of specific radiopharmaceuticals to image and predict therapy response in breast cancer and neuroendocrine tumors since they represent a paradigmatic example of the impor</pubmed_abstract><journal>Cancers</journal><pagination>E781</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7226069</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.</pubmed_title><pmcid>PMC7226069</pmcid><pubmed_authors>Panzuto F</pubmed_authors><pubmed_authors>Marchetti P</pubmed_authors><pubmed_authors>Glaudemans AWJM</pubmed_authors><pubmed_authors>Signore A</pubmed_authors><pubmed_authors>Varani M</pubmed_authors><pubmed_authors>Onofrio L</pubmed_authors><pubmed_authors>Auletta S</pubmed_authors><pubmed_authors>Lauri C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.</name><description>Molecular medicine has gained clinical relevance for the detection and staging of oncological diseases, to guide therapy decision making and for therapy follow-up due to the availability of new highly sensitive hybrid imaging camera systems and the development of new tailored radiopharmaceuticals that target specific molecules. The knowledge of the expression of different receptors on the primary tumor and on metastases is important for both therapeutic and prognostic purposes and several approaches are available aiming to achieve personalized medicine in different oncological diseases. In this review, we describe the use of specific radiopharmaceuticals to image and predict therapy response in breast cancer and neuroendocrine tumors since they represent a paradigmatic example of the impor</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Mar</publication><modification>2025-04-19T03:58:16.829Z</modification><creation>2021-02-19T22:05:16Z</creation></dates><accession>S-EPMC7226069</accession><cross_references><pubmed>32218303</pubmed><doi>10.3390/cancers12040781</doi></cross_references></HashMap>